Results 21 to 30 of about 12,211 (152)
Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
PLoS ONE, 2012 In multiple sclerosis (MS), treatment with the monoclonal antibody natalizumab effectively reduces the formation of acute lesions in the central nervous system (CNS).
Lars Börnsen +6 more
doaj +1 more source
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
Therapeutic Advances in Neurological Disorders, 2023 Background: Natalizumab is a highly effective monoclonal antibody for the treatment of multiple sclerosis (MS), which can diffuse in different anatomical compartments, including cerebrospinal fluid (CSF) and milk.
Ilaria Callegari +12 more
doaj +1 more source
Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis
European Journal of Case Reports in Internal Medicine, 2019 Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability.
Marina Rodrigues Lima +3 more
doaj +1 more source
The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
Therapeutic Advances in Neurological Disorders, 2017 Natalizumab, a monoclonal antibody that blocks lymphocyte infiltration in the central nervous system, is a valuable tool in the treatment of relapsing forms of multiple sclerosis (MS). In a phase III clinical trial comparing natalizumab with placebo over
Barry A. Singer
doaj +1 more source
High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients
Therapeutic Advances in Neurological Disorders, 2021 Aims: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion in natalizumab-treated patients. Background: Natalizumab is highly effective for the treatment of relapsing–remitting multiple sclerosis (RRMS), but its ...
Christopher M. Dwyer +16 more
doaj +1 more source
Natalizumab for relapsing-remitting multiple sclerosis
Neurología (English Edition), 2011 Introduction: Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of relapsing-remitting multiple sclerosis.
A. Horga, M. Tintoré
doaj +1 more source
AboutOpenBackground: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS).
Roberto Bergamaschi +2 more
doaj +1 more source
Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort
Acta Médica Portuguesa, 2014 Introduction: Natalizumab is licensed as monotherapy for relapsing–remitting multiple sclerosis. Since pivotal studies showing natalizumab efficacy, several subsequent studies confirmed the reduction in annualized relapse rate and the slowing of ...
Ana Teresa Carvalho +2 more
doaj +1 more source
Clinical and Translational Medicine, 2018 Multiple sclerosis (MS) is a progressive immune-related disorder of the central nervous system leading to destruction of myelin sheaths. Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin which has been approved
Mehrdokht Mazdeh +3 more
doaj +1 more source
Frontiers in Immunology, 2021 ObjectiveTo determine the transfer of the monoclonal antibody natalizumab into breastmilk and to evaluate drug and serum neurofilament light chain ((s)NfL) levels in natalizumab exposed pregnancies and lactation periods.MethodsEleven women with relapsing
Undine Proschmann +4 more
doaj +1 more source